Fig. 5

Dapagliflozin (DAPA) protects heart function on ischemia/reperfusion injury. 

Measurement in echocardiography, including (a) ejection fraction (EF), (b) fractional shortening (FS), (c) left ventricular end-diastolic volume (LV Vol d), (d) left ventricular end-systolic volume (LV Vol s), (e) left ventricular internal dimension at end-diastole (LVIDd), and (f) left ventricular internal dimension at end-systole (LVIDs), were shown. (g) Representative echocardiographic M-mode images from animals in different conditions revealed reduced motion of anterior wall of left ventricle caused by ischemia/reperfusion (I/R) (middle panel), which was attenuated by DAPA treatment (lower panel). Red arrows indicate the motion of anterior wall of left ventricle. The data were presented as the mean ± SD in sham control, ischemia/reperfusion (I/R), and I/R plus DAPA treatment animals, eight animals in each group (* indicating p < 0.05 compared with the control group; # indicating p < 0.05 compared to I/R without DAPA treatment)